Skip to main content
. 2012 May 17;7(5):e37416. doi: 10.1371/journal.pone.0037416

Figure 5. Immunoblot analysis of tubulysin A- or pretubulysin-treated L3.6pl pancreatic cancer cells.

Figure 5

The cells were treated for the indicated time points with 10 nM tubulysin A or 10 nM pretubulysin. Lysates were immunoblotted for A) Bcl-2 and phosphorylated Bcl-2 (pBcl-2) or B) for PARP; β-actin served as a reference for the quantification of the protein levels. Ctrl.: lysates of untreated control cells.